Entero Therapeutics, Inc. Announces Corporate Name Change to GridAI Technologies Corp. and New Ticker Symbol "GRDX"

Rhea-AI Summary

Entero Therapeutics (NASDAQ:ENTO) will change its name to GridAI Technologies Corp. and its ticker to GRDX, effective at 12:01 AM/ET on December 1, 2025. The change follows the Company's acquisition of 100% of GRID AI Corp, a grid-edge AI software and controls platform for utilities, retail energy providers, and large power users. The Company's common stock will begin trading on the Nasdaq Capital Market under the new name and symbol on December 1, 2025. The company said the name and ticker changes do not alter its legal structure, operations, or financial reporting, and shareholders are not required to take any action.

Positive

• Acquired 100% of GRID AI Corp
• Name change effective 12:01 ET, Dec 1, 2025
• Ticker GRDX begins trading on Nasdaq Dec 1, 2025

Negative

• None.

BOCA RATON, FL / ACCESS Newswire / November 28, 2025 / Entero Therapeutics, Inc. (NASDAQ:ENTO) (the "Company") today announced that it will change its name to GridAI Technologies Corp., effective at 12:01 Eastern Time on Monday, December 1, 2025. The name change closely aligns the Company's business following its acquisition of 100% of GRID AI Corp ("GRID AI"), a grid-edge, AI-driven software and controls platform that enables utilities, retail energy providers, and large power users to dynamically manage load and distributed energy resources including battery energy storage systems. In connection with the name change, the Company will change its ticker symbol to "GRDX". The Company's common stock will commence trading on the Nasdaq Capital Market exchange under the new name and trading symbol on December 1, 2025.

"This marks the beginning of a new chapter for the business," said Jason Sawyer, Interim Chief Executive Officer of GridAI Technologies Corp. "Our mission is to enhance grid-edge intelligence using AI, machine learning and edge analytics by orchestrating supply and demand in real time, creating a more reliable, resilient, and transactive grid -now supported with our public-company platform - and this name change reflects that commitment."

The name and future ticker change do not affect the Company's legal structure, business operations, or existing financial reporting obligations. Shareholders are not required to take any action in connection with the change.

Further updates will be provided via regular press releases and regulatory filings.

About Entero Therapeutics, Inc. (NASDAQ:ENTO)
Entero Therapeutics, Inc. is a publicly listed company on Nasdaq. The Company is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company's programs address significant unmet needs in GI health and comprise development of Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. Following completion of the GRID AI acquisition, the Company intends to continue these prior operations and to also operate GRID AI as a wholly owned subsidiary and pursue opportunities at the intersection of AI and energy infrastructure.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding strategic benefits of the acquisition, market opportunities, product capabilities, stockholder approval of the transaction, Nasdaq's approval of an initial listing application, if any, and future operating results. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Important factors include, among others, our business strategy; the risk that regulatory or third-party approvals are delayed or not obtained; integration challenges; market adoption; competitive dynamics; macroeconomic and energy-market conditions; and other risks detailed from time to time in the Company's SEC filings. The Company undertakes no obligation to update forward-looking statements.

Investor & Media Contacts:
Entero Investor Relations
investors@enterothera.com

SOURCE: Entero Therapeutics, Inc.

View the original press release on ACCESS Newswire

FAQ

When will Entero Therapeutics change its name to GridAI Technologies and ticker to GRDX?

The name and ticker change take effect at 12:01 ET on December 1, 2025, with trading under GRDX starting that day.

What does the acquisition of GRID AI mean for ENTO shareholders?

The company acquired 100% of GRID AI Corp; the announcement says this aligns the business to grid-edge AI operations.

Do shareholders need to take any action for ENTO to become GRDX?

No action is required by shareholders; the company stated shareholders do not need to take any steps.

Will the company's legal structure or reporting change after the name switch to GridAI (GRDX)?

The company said the name and ticker change do not affect legal structure, business operations, or financial reporting obligations.

What markets and customers does GRID AI serve following Entero's acquisition?

GRID AI provides grid-edge AI software and controls for utilities, retail energy providers, and large power users.

Where will investors find future updates about GridAI Technologies (GRDX)?

The company will provide further updates via regular press releases and regulatory filings.